Programs

Focusing on significant areas of unmet medical need

Vesigen’s therapeutic programs using ARMMs technology have the potential to provide novel treatments for patients in a wide range of disease areas.

Disease areas of focus

Vesigen is pursuing multiple programs through both in-house development and collaborations, currently focusing on the following disease areas:

Neurology

Delivery to the central nervous system, particularly into neurons, has proven extremely challenging for existing technologies. Vesigen is exploring ARMMs-based therapeutic programs targeting neurological diseases for which there are no available treatments.

Ocular

Current technologies for systemic and topical delivery of ophthalmologic therapies are inefficient and often limited by tolerability issues, and intravitreal injections are invasive and require direct physician involvement. Vesigen is developing therapeutic programs using ARMMs technology to overcome current limitations and improve options for patients.

Immune Modulation

Numerous validated intracellular targets in immunology remain undruggable and/or not accessible for gene editing, protein delivery, or RNA interference using existing drug delivery systems. Vesigen has demonstrated high-efficiency in vivo gene editing of this class of targets in difficult-to-reach cell types paving the way for safer and more efficacious therapeutic interventions.

Explore a partnership

Interested in partnering with Vesigen?